Subscribe to our Newsletters !!
There is one fact about life on Earth we cannot es
Enter any scientific lab and among the first tools
The Nobel Prize in Physiology or Medicine awarded
Shilpa Medicare – the full-service contract de
Alembic Pharmaceutica
Tofu has been a favorite food for vegetarians and
Dear Readers, Welcome to the latest issue of Micr
An announcement made by Agilent Technologies describes that the company has completed it's acquisition of Bio Tek instruments.
As Agilent Technologies, Inc. has announced complete acquisition of Biotek instruments, it has promised the expansion of Agilent's expertise and presence in the cell analysis. This acquisition upgrades the company's place in the growing and huge immuno-oncology and immunotherapy areas.
BioTek Instruments is a globally renowned company working on the design, manufacture and distribution of innovative life science instrumentation.
This acquisition will benifit the company in so many ways and in different areas as well. The presence of the company in biopharma, academia and research is going to witness expansion because customers also are keenly interested in understanding complex cellular interactions and environment. This collaboration will stand for Agilent to deliver a range of unique cell analysis workflows to feed customers with the competence to obtain deeper, more dependable insights across a variety of cell analysis applications.
"We're extremely pleased to add BioTek's tremendously talented employees and industry leading technologies to the Agilent team," said Mike McMullen, Agilent president and CEO. "The combination of our two companies and our collective offerings will help lead to a better understanding of cell function, behavior and interactions. This will enable researchers to more quickly achieve significant breakthroughs in solving the most complex health and science challenges."
In Agilent's fiscal year fourth quarter, it's expected that BioTek will contribute approximately $20 million to $25 million to Agilent revenues with no material impact on fourth quarter earnings per share (EPS).
